Compare MBINM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBINM | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | 663 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | MBINM | VCEL |
|---|---|---|
| Price | $25.46 | $37.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | N/A | ★ 577.0K |
| Earning Date | N/A | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $147.15 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | N/A | $29.24 |
| 52 Week High | N/A | $63.00 |
| Indicator | MBINM | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 50.84 |
| Support Level | $25.10 | $35.85 |
| Resistance Level | $25.64 | $39.07 |
| Average True Range (ATR) | 0.23 | 1.82 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 46.75 | 39.08 |
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.